59.什么是 TERT?- 端粒酶逆转录酶案例研究

IF 1.4 4区 医学 Q4 GENETICS & HEREDITY
Yeshmira Moodley, Longqian Yang, Bronwyn Neumann, Amanda Dixon-McIver
{"title":"59.什么是 TERT?- 端粒酶逆转录酶案例研究","authors":"Yeshmira Moodley,&nbsp;Longqian Yang,&nbsp;Bronwyn Neumann,&nbsp;Amanda Dixon-McIver","doi":"10.1016/j.cancergen.2024.08.061","DOIUrl":null,"url":null,"abstract":"<div><div>Telomerase reverse transcriptase is a catalytic subunit of the telomerase protein that is involved in the maintenance of genomic stability. <em>TERT</em> aberrations are important biomarkers in the diagnosis, prognosis, and treatment of many human cancers. The <em>TERT</em> promoter has proven to be a difficult region of testing amongst a variety of currently available technologies.</div><div><em>TERT</em> promoter mutation analysis was performed on brain tissue of a 62-year old male meningioma patient using MALDI-TOF (Agena Bioscience MassARRAY platform) and detected a low frequency <em>TERT</em> mutation. The pathologist questioned the result and sent some of the sample for additional testing to 2 different referral laboratories - one aliquot was sent for Pyrosequencing and the other for NGS - both with a higher limit of detection than MALDI-TOF. Neither methodology detected a <em>TERT</em> mutation. On the basis of these result the diagnosis was changed.</div><div>Certain of our <em>TERT</em> mutation, an aliquot of the remaining extracted DNA was sent for digital droplet PCR (ddPCR) which has the same limit of detection as our MALDI-TOF platform. A <em>TERT</em> mutation was confirmed.</div><div>This case highlights the challenges in <em>TERT</em> promoter mutation analysis as well as the significance of confirmatory testing. The importance of confirming results using platforms with an appropriate limit of detection is paramount in reducing under-reporting of low level mutations of clinical significance.</div></div>","PeriodicalId":49225,"journal":{"name":"Cancer Genetics","volume":"286 ","pages":"Page S19"},"PeriodicalIF":1.4000,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"59. What the TERT? - A telomerase reverse transcriptase case study\",\"authors\":\"Yeshmira Moodley,&nbsp;Longqian Yang,&nbsp;Bronwyn Neumann,&nbsp;Amanda Dixon-McIver\",\"doi\":\"10.1016/j.cancergen.2024.08.061\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><div>Telomerase reverse transcriptase is a catalytic subunit of the telomerase protein that is involved in the maintenance of genomic stability. <em>TERT</em> aberrations are important biomarkers in the diagnosis, prognosis, and treatment of many human cancers. The <em>TERT</em> promoter has proven to be a difficult region of testing amongst a variety of currently available technologies.</div><div><em>TERT</em> promoter mutation analysis was performed on brain tissue of a 62-year old male meningioma patient using MALDI-TOF (Agena Bioscience MassARRAY platform) and detected a low frequency <em>TERT</em> mutation. The pathologist questioned the result and sent some of the sample for additional testing to 2 different referral laboratories - one aliquot was sent for Pyrosequencing and the other for NGS - both with a higher limit of detection than MALDI-TOF. Neither methodology detected a <em>TERT</em> mutation. On the basis of these result the diagnosis was changed.</div><div>Certain of our <em>TERT</em> mutation, an aliquot of the remaining extracted DNA was sent for digital droplet PCR (ddPCR) which has the same limit of detection as our MALDI-TOF platform. A <em>TERT</em> mutation was confirmed.</div><div>This case highlights the challenges in <em>TERT</em> promoter mutation analysis as well as the significance of confirmatory testing. The importance of confirming results using platforms with an appropriate limit of detection is paramount in reducing under-reporting of low level mutations of clinical significance.</div></div>\",\"PeriodicalId\":49225,\"journal\":{\"name\":\"Cancer Genetics\",\"volume\":\"286 \",\"pages\":\"Page S19\"},\"PeriodicalIF\":1.4000,\"publicationDate\":\"2024-08-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Cancer Genetics\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S2210776224000991\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"GENETICS & HEREDITY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer Genetics","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2210776224000991","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"GENETICS & HEREDITY","Score":null,"Total":0}
引用次数: 0

摘要

端粒酶逆转录酶是端粒酶蛋白的催化亚基,参与维持基因组的稳定性。TERT畸变是诊断、预后和治疗许多人类癌症的重要生物标志物。使用 MALDI-TOF(Agena Bioscience MassARRAY 平台)对一名 62 岁男性脑膜瘤患者的脑组织进行了 TERT 启动子突变分析,检测到了低频 TERT 突变。病理学家对这一结果提出质疑,并将部分样本送往两个不同的转诊实验室进行额外检测,其中一个样本被送往热测序实验室,另一个样本被送往 NGS 实验室,这两个实验室的检测限均高于 MALDI-TOF。两种方法都没有检测到 TERT 突变。在这些结果的基础上,我们改变了诊断。在确定了 TERT 突变后,我们将剩余提取的 DNA 样本送去进行数字液滴 PCR (ddPCR),其检测限与我们的 MALDI-TOF 平台相同。该病例凸显了 TERT 启动子突变分析所面临的挑战以及确证检测的重要性。使用具有适当检测限的平台确认结果对于减少具有临床意义的低水平突变的漏报至关重要。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
59. What the TERT? - A telomerase reverse transcriptase case study
Telomerase reverse transcriptase is a catalytic subunit of the telomerase protein that is involved in the maintenance of genomic stability. TERT aberrations are important biomarkers in the diagnosis, prognosis, and treatment of many human cancers. The TERT promoter has proven to be a difficult region of testing amongst a variety of currently available technologies.
TERT promoter mutation analysis was performed on brain tissue of a 62-year old male meningioma patient using MALDI-TOF (Agena Bioscience MassARRAY platform) and detected a low frequency TERT mutation. The pathologist questioned the result and sent some of the sample for additional testing to 2 different referral laboratories - one aliquot was sent for Pyrosequencing and the other for NGS - both with a higher limit of detection than MALDI-TOF. Neither methodology detected a TERT mutation. On the basis of these result the diagnosis was changed.
Certain of our TERT mutation, an aliquot of the remaining extracted DNA was sent for digital droplet PCR (ddPCR) which has the same limit of detection as our MALDI-TOF platform. A TERT mutation was confirmed.
This case highlights the challenges in TERT promoter mutation analysis as well as the significance of confirmatory testing. The importance of confirming results using platforms with an appropriate limit of detection is paramount in reducing under-reporting of low level mutations of clinical significance.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Cancer Genetics
Cancer Genetics ONCOLOGY-GENETICS & HEREDITY
CiteScore
3.20
自引率
5.30%
发文量
167
审稿时长
27 days
期刊介绍: The aim of Cancer Genetics is to publish high quality scientific papers on the cellular, genetic and molecular aspects of cancer, including cancer predisposition and clinical diagnostic applications. Specific areas of interest include descriptions of new chromosomal, molecular or epigenetic alterations in benign and malignant diseases; novel laboratory approaches for identification and characterization of chromosomal rearrangements or genomic alterations in cancer cells; correlation of genetic changes with pathology and clinical presentation; and the molecular genetics of cancer predisposition. To reach a basic science and clinical multidisciplinary audience, we welcome original full-length articles, reviews, meeting summaries, brief reports, and letters to the editor.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信